



Chinese American Hematologist and Oncologist Network
美国华裔血液与肿瘤专家学会

June 6, 2020

Dear CAHON Members,

As you know, the CAHON leadership transition took place on June 1, 2020. Dr. Chongxian Pan began his CAHON Presidency and I began my role as Board Chair for 2020-2022. Now I am pleased to announce that the CAHON Board of Directors has unanimously voted to elect RuiRong Yuan, MD, PhD to serve as the Board Chair-Elect for the 2020-2022 term, ascending to Board Chair for the 2022-2024 term.



Dr. RuiRong Yuan is the Medical Head of Novartis Oncology Emerging Growth Markets (EGM: Asia-Pacific, Middle East, South Africa, China, Turkey and Australia). She previously served as the President, Chief Medical Officer (CMO) and Board Director of Adlai Nortye Biopharma; CMO & President of global clinical development at BeiGene; CMO of Eisai Global Oncology, Head of Oncology MA at Daiichi Sankyo (US) and senior global clinical leader at Novartis Oncology. Dr. Yuan has decades of successful R&D and MA experience and played a critical leadership role in the new drug development, regulatory approval, life cycle management and commercialization of multiple compounds.

Dr. Yuan is a board certified medical oncologist and has extensive academic clinical practice and research experience as a physician-scientist. She completed her internal medicine residency training at the Albert Einstein College of Medicine and clinical hem/onc fellowship at Cancer Hospital of Peking Union Medical College in China, Bellinzona Hospital of South Swiss Cancer Institute and Memorial Sloan Kettering Cancer Center in New York. Prior to moving to pharmaceutical industry, Dr. Yuan was a faculty member and assistant professor at New Jersey Medical School and served as Chief of the Tumor and Neuroimmunology research laboratories at VA Medical center, where she remains on staff as attending hematologist and oncologist. She has published many peer-reviewed original research articles and holds multiple patents related to either cancer treatment or autoimmune disease therapy.

For many years, Dr. Yuan has been actively involved in promoting cancer research collaboration between Eastern and Western hematology and oncology communities. Dr. Yuan is one of the founding CAHON members, a strong supporter and a passionate leader of the organization.

We look forward to meeting again in person soon, but in the meantime, I invite you to join me in welcoming RuiRong in her new leadership role on the Board.

Sincerely,

Wenru Song, MD, PhD
CAHON Board Chair